DK0895988T3 - Arylsulfonylaminohydroxamsyrederivater - Google Patents

Arylsulfonylaminohydroxamsyrederivater

Info

Publication number
DK0895988T3
DK0895988T3 DK98305959T DK98305959T DK0895988T3 DK 0895988 T3 DK0895988 T3 DK 0895988T3 DK 98305959 T DK98305959 T DK 98305959T DK 98305959 T DK98305959 T DK 98305959T DK 0895988 T3 DK0895988 T3 DK 0895988T3
Authority
DK
Denmark
Prior art keywords
aryl
hydroxamic acid
arylsulfonylamino hydroxamic
angiogenisis
occular
Prior art date
Application number
DK98305959T
Other languages
Danish (da)
English (en)
Inventor
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0895988T3 publication Critical patent/DK0895988T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DK98305959T 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsyrederivater DK0895988T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5520897P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
DK0895988T3 true DK0895988T3 (da) 2002-09-09

Family

ID=21996365

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98305959T DK0895988T3 (da) 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsyrederivater

Country Status (9)

Country Link
EP (1) EP0895988B1 (de)
JP (1) JPH11116549A (de)
AT (1) ATE217863T1 (de)
BR (1) BR9803128A (de)
CA (1) CA2244501C (de)
DE (1) DE69805473T2 (de)
DK (1) DK0895988T3 (de)
ES (1) ES2176913T3 (de)
PT (1) PT895988E (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
WO2000058280A1 (fr) * 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
EP1041072B1 (de) * 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentylhydroxamsäure
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
PL365444A1 (en) 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
WO2001077092A1 (en) * 2000-04-07 2001-10-18 Samsung Electronics Co., Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
WO2002072577A2 (en) * 2001-03-14 2002-09-19 Novartis Ag Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
KR20040023630A (ko) 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
US7176217B2 (en) 2001-11-13 2007-02-13 Shiseido Co., Ltd. Azabicyclo compound matrix metalloprotease inhibitor and skin preparation
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7504537B2 (en) 2001-12-27 2009-03-17 Dainippon Sumitomo Pharma Co., Ltd. Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
EP1694410B1 (de) 2003-12-15 2010-04-14 Japan Tobacco, Inc. Cyclopropanderivate und ihre pharmazeutische verwendung
KR20060109937A (ko) * 2003-12-15 2006-10-23 니뽄 다바코 산교 가부시키가이샤 Ｎ-치환-ｎ-술포닐아미노시클로프로판 화합물 및 그의약제학적 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE182581T1 (de) * 1994-06-22 1999-08-15 British Biotech Pharm Metalloproteinase-inhibitoren
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP2000501423A (ja) * 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体

Also Published As

Publication number Publication date
CA2244501A1 (en) 1999-02-08
JPH11116549A (ja) 1999-04-27
EP0895988A1 (de) 1999-02-10
DE69805473T2 (de) 2003-01-16
ATE217863T1 (de) 2002-06-15
BR9803128A (pt) 2000-05-02
ES2176913T3 (es) 2002-12-01
PT895988E (pt) 2002-09-30
CA2244501C (en) 2003-03-18
EP0895988B1 (de) 2002-05-22
DE69805473D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
DK0895988T3 (da) Arylsulfonylaminohydroxamsyrederivater
MX9706850A (es) Derivados de acido arilsulfonilaminohidroxiamico, composiciones que los contienen y uso de los mismos.
EP0818442A3 (de) Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
MX9708026A (es) Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
EA199900139A1 (ru) Производные арилсульфониламиногидроксамовой кислоты
WO1991002716A3 (en) Hydroxamic acid based collagenase inhibitors
FR2744010B1 (fr) Procede de fabrication d'implants osseux
GB2290543B (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
AP9801174A0 (en) Cyclic sulfone derivatives.
WO2004024081A3 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
YU37499A (sh) Derivati arilsulfonil hidroksamske kiseline
NO984112D0 (no) Hydroksyaminsyrederivater for anvendelse ved behandling av sykdommer relatert til bindevevdegradering
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
DK1134215T3 (da) 2-oxo-imidazolidin-4-carboxylsyrehydroxaminforbindelser, som inhiberer matrixmetalloproteinaser
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
WO2000015208A3 (en) New use of immunosupressants for mmp-mediated diseases
EA199800181A1 (ru) Производные эпоксиянтарной кислоты
CA2253796A1 (en) Inhibition of matrix metalloproteases by acetylene containing compounds
AU2723192A (en) Thiadiazinone
WO2001082911A3 (en) TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
UA35749A (uk) Спосіб лікування карієсу
CA2244903A1 (en) Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation
IT1303766B1 (it) Alesatore-rettificatore di cavita' chirurgiche ossee destinate adaccogliere impianti.
ID21321A (id) Senyawa-senyawa betha-laktam untuk pengobatan penyakit infeksi disebabkan mikroorganisme penghasil betha-laktamase